Mesnex

(mesna)

ApprovedSmall molecule

Mesna is used to protect the bladder from damage caused by certain chemotherapy drugs, particularly when patients receive high-dose chemotherapy treatment for cancer.[2] Mesnex is currently approved and in use across 30 indications[4].[1]

Mesnex is one of 541 small molecule programs targeting Ependymoma. It is currently in Approved.

Indications

168

Total Trials

Active Trials

540

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

EpendymomaActive, not recruiting

Non-Hodgkins LymphomaApproved

ThrombocytopeniaActive, not recruiting

LeukemiaCompleted

Connective and Soft Tissue NeoplasmActive, not recruiting

NeuroblastomaCompleted

MyopathyApproved

RetinoblastomaActive, not recruiting

Ewing SarcomaActive, not recruiting

Neuromyelitis OpticaApproved

EpendymomaPhase 3

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

ThrombocytopeniaApproved

Active, not recruiting

LeukemiaPhase 3

Completed

Connective and Soft Tissue NeoplasmApproved

Active, not recruiting

NeuroblastomaPhase 3

Completed

MyopathyApproved

Approved

RetinoblastomaPhase 2

Active, not recruiting

Ewing SarcomaPhase 2

Active, not recruiting

Neuromyelitis OpticaApproved

Approved

Showing 10 of 30 indications

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Phase 3

43 2

Fludara

Sanofi

Phase 3

47 3

Venclexta

AbbVie

Phase 3

17 4

Biaxin

AbbVie

Phase 3

14 5

Mesnex

BBaxter Healthcare Corporation

Approved

1 6

Treanda

AAzurity Pharmaceuticals

Phase 3

19 7

Vepesid

AAvyxa

Phase 3

17 8

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 9

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Phase 2Active, not recruiting

Hematopoietic Cell Transplantation

NCT04904588

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT06001385

Phase 2Active, not recruiting

Lymphoma

NCT02436707

Q1 2027

Phase 2Active, not recruiting

Retinoblastoma

NCT01783535

Phase 1Recruiting

Patients With Solid Tumors

NCT04897321

Clinical

Trials by Indication[1]

Lymphoma17 trials

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

Completed·UUniversity of Wisconsin, Madison·N/A·NCT02652468·11 enrolled

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Withdrawn·WWestern Regional Medical Center·Phase 1/2·NCT02408042

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00006373·27 enrolled

Show 14 more trials

Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01329900·50 enrolled

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Terminated·—·Phase 2·NCT00126191·10 enrolled

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002691

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002565·61 enrolled

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed·TTemple University·Phase 1/2·NCT00002510

Tandem Auto-Allo Transplant for Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01181271·42 enrolled

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Unknown status·BBritish Columbia Cancer Agency·Phase 2·NCT00324467·150 enrolled

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00439361·14 enrolled

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01169636·62 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002941·69 enrolled

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Completed·PPolish Lymphoma Research Group·Phase 2·NCT01481272·77 enrolled

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00290433·55 enrolled

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02106988·26 enrolled

A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT02436707·129 enrolled

Acute Lymphoblastic Leukemia14 trials

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06777979·30 enrolled

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002704·156 enrolled

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002816·120 enrolled

Show 11 more trials

Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia

Completed·WWashington University School of Medicine·Phase 1·NCT01331590·13 enrolled

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Withdrawn·MMayo Clinic·Phase 2·NCT01670084

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Terminated·—·Phase 3·NCT00002961·43 enrolled

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04752163·17 enrolled

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00941928·2 enrolled

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00671658·220 enrolled

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002785

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07257419·70 enrolled

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06001385·313 enrolled

Leukemia9 trials

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002494·134 enrolled

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06847269·25 enrolled

Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00038610·54 enrolled

Show 6 more trials

Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00667927·17 enrolled

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002549·1,520 enrolled

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Completed·WWake Forest University Health Sciences·Phase 2·NCT00002865·25 enrolled

RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00968253·24 enrolled

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04318678·108 enrolled

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Completed·—·Phase 1·NCT00057005·6 enrolled

Neuroblastoma8 trials

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT01798004·150 enrolled

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT00002740·30 enrolled

Show 5 more trials

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00698009·1 enrolled

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Completed·—·Phase 2·NCT00165139·20 enrolled

Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma

Completed·—·Phase 2·NCT00578864·13 enrolled

Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04947501·26 enrolled

Breast Cancer7 trials

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00048893·37 enrolled

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

Completed·EETOP IBCSG Partners Foundation·Phase 3·NCT00002784·344 enrolled

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Unknown status·SSt. Louis University·Phase 1/2·NCT00002627·30 enrolled

Show 4 more trials

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

Completed·TTemple University·Phase 1/2·NCT00002509

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Completed·—·Phase 2·NCT00006260·36 enrolled

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Louis University·Phase 1/2·NCT00002628·50 enrolled

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Completed·—·Phase 2·NCT00003042·41 enrolled

74 more indications

Stem Cell Transplantation6 trials

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00473551·4 enrolled

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE

Terminated·—·N/A·NCT00578461·26 enrolled

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02880293·44 enrolled

Show 3 more trials

Stem Cell Transplantation in Crohn's Disease

Recruiting·—·Phase 1/2·NCT04224558·15 enrolled

Stem Cell Transplantation for Stiff Person Syndrome (SPS)

Terminated·NNorthwestern University·Phase 1/2·NCT02282514·23 enrolled

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Completed·—·Phase 1·NCT00002854·33 enrolled

Bone Marrow Transplantation5 trials

Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004323·10 enrolled

Bone Marrow Transplantation in Treating Patients With Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002829·45 enrolled

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Unknown status·VVanderbilt-Ingram Cancer Center·N/A·NCT01850108·26 enrolled

Show 2 more trials

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002634·45 enrolled

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02702960

Soft Tissue Sarcoma5 trials

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03283696·24 enrolled

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00002791

A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00001300·150 enrolled

Show 2 more trials

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002804·43 enrolled

A Phase I/II Trial of Neoadjuvant ADI-PEG 20 in Combination With Ifosfamide and Radiotherapy in Soft Tissue Sarcoma (STS)

Terminated·WWashington University School of Medicine·Phase 1·NCT05813327·6 enrolled

Systemic Sclerosis4 trials

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Terminated·NNorthwestern University·Phase 3·NCT01445821·44 enrolled

Cardiac Safe Transplants for Systemic Sclerosis

Terminated·NNorthwestern University·Phase 2/3·NCT03593902·9 enrolled

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Completed·—·Phase 1·NCT00058578·24 enrolled

Show 1 more trial

Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc)

Recruiting·PPaul Szabolcs·Phase 2·NCT03630211·8 enrolled

Multiple Sclerosis3 trials

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

Completed·—·Phase 2·NCT00040482·10 enrolled

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Suspended·IIndapta Therapeutics, INC.·Phase 1·NCT06677710·34 enrolled

Maximizing Outcome of Multiple Sclerosis Transplantation

Terminated·NNorthwestern University·Phase 3·NCT03342638·66 enrolled

Chemotherapy3 trials

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Terminated·MM.D. Anderson Cancer Center·N/A·NCT00673179·7 enrolled

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00936936·64 enrolled

Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)

Completed·MM.D. Anderson Cancer Center·N/A·NCT00410488·51 enrolled

Osteosarcoma3 trials

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

Terminated·UUniversity of Chicago·Phase 1·NCT01258634·2 enrolled

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Completed·CChildren's Oncology Group·Phase 1·NCT00742924·24 enrolled

A Phase II Study Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT07428993·41 enrolled

Acute Lymphoblastic Leukaemia2 trials

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Unknown status·SSabz Biomedicals·Phase 1·NCT04653493·22 enrolled

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT03821610·242 enrolled

Hematological Malignancies2 trials

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06326463·18 enrolled

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT05579769·3 enrolled

Mantle Cell Lymphoma2 trials

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00878254·25 enrolled

R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma

Completed·UUniversity of Miami·Phase 2·NCT00450801·22 enrolled

Germ Cell Tumor2 trials

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Completed·CChildren's Oncology Group·N/A·NCT00066482·19 enrolled

Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00432094·23 enrolled

Medulloblastoma2 trials

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00002875·421 enrolled

Hematologic Malignancies2 trials

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT02199041·24 enrolled

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Withdrawn·OOssium Health, Inc.·Phase 1·NCT05170828

Hematopoietic Stem Cell Transplant2 trials

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Hematopoietic Stem Cell Transplant in Devic's Disease

Completed·NNorthwestern University·Phase 1/2·NCT00787722·13 enrolled

Memory2 trials

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT02790515·170 enrolled

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Retinoblastoma2 trials

Chemotherapy in Treating Patients With Retinoblastoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002675·50 enrolled

Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01783535·174 enrolled

Stem Cell Transplant2 trials

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00857389·60 enrolled

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE

Terminated·—·N/A·NCT00578539·24 enrolled

Transplantation2 trials

Umbilical Cord Blood Transplantation From Unrelated Donors

Recruiting·UUniversity of Rochester··NCT03016806·30 enrolled

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Ependymoma2 trials

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01096368·479 enrolled

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Completed·CChildren's Oncology Group·Phase 2·NCT00027846·378 enrolled

Sickle Cell Disease2 trials

Siplizumab for Sickle Cell Disease Transplant

Terminated·—·Phase 1/2·NCT06078696·1 enrolled

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)

Completed·MMedical College of Wisconsin·Phase 2·NCT03263559·95 enrolled

Melanoma2 trials

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Withdrawn·JJames Isaacs, MD·Phase 1·NCT06190249

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00338377·1,230 enrolled

Acute Lymphoblastic Leukemia, in Relapse2 trials

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04881240·60 enrolled

SJCAR19: A Phase I/II Study Evaluating SJCAR19 (CD19-Specific CAR Engineered Autologous T-Cells) in Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia

Active, not recruiting·SSt. Jude Children's Research Hospital·Preclinical·NCT03573700·24 enrolled

Ewing's Sarcoma1 trial

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00061893·38 enrolled

Liver Transplant1 trial

Liver Transplantation With Tregs at UCSF

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03654040·42 enrolled

Vasculitis1 trial

Hematopoietic Stem Cell Support in Vasculitis

Terminated·NNorthwestern University·Phase 1·NCT00278512·7 enrolled

Severe Aplastic Anemia1 trial

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02224872·18 enrolled

Myeloid Malignancies1 trial

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT05115630·24 enrolled

Tolerance1 trial

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02029638·4 enrolled

NMO Spectrum Disorder1 trial

Autologous Transplant To End NMO Spectrum Disorder

Withdrawn·NNorthwestern University·Phase 2/3·NCT03829566

Fibrosarcoma1 trial

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Terminated·CChildren's Oncology Group·Phase 2·NCT00072280·7 enrolled

Lymphoid Malignancies1 trial

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03056339·49 enrolled

Adenocarcinoma1 trial

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Terminated·CCelularity Incorporated·Phase 1/2·NCT05207722·1 enrolled

Kidney Cancer1 trial

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00091611·3 enrolled

Necrosis1 trial

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

Completed·MMara Chambers·Phase 2·NCT01205503·32 enrolled

Radiation Therapy1 trial

Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma

Unknown status·UUniversity Hospital Muenster·Phase 3·NCT00002516

Solid Tumors1 trial

MT2004-30: Tomotherapy for Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00623077·23 enrolled

Ewing sarcoma1 trial

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01864109·83 enrolled

Multiple Myeloma1 trial

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Completed·—·Phase 4·NCT01731886·60 enrolled

APL1 trial

IS-free Treg HaploHCT

Recruiting·—·Phase 1·NCT04678401·30 enrolled

Small Cell Lung Cancer1 trial

Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00002822·400 enrolled

Metastatic Cancer1 trial

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00924287·1 enrolled

Completed·—·Phase 1·NCT02167958·28 enrolled

TED1 trial

Chemically Assisted Capsulectomy-A New Clinical Approach

Terminated·VVanderbilt University·N/A·NCT00758667·20 enrolled

Vomiting1 trial

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02732015·37 enrolled

Thalassemia1 trial

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

Terminated·—·N/A·NCT00578292·10 enrolled

Autologous Stem Cell Transplantation1 trial

Autologous Stem Cell Transplantation for Crohn's Disease

Recruiting·PPaul Szabolcs·Phase 1/2·NCT00692939·20 enrolled

Patients With Solid Tumors1 trial

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT04897321·32 enrolled

Graft-versus-host-disease (GVHD)1 trial

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT00429416·14 enrolled

Hematopoietic Cell Transplantation1 trial

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Active, not recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT04904588·300 enrolled

Hematologic Malignancy1 trial

Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01807611·82 enrolled

Systemic Lupus Erythematosus1 trial

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00076752·9 enrolled

Randomized1 trial

Randomized Double Cord Blood Transplant Study

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067002·110 enrolled

Myasthenia Gravis1 trial

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Terminated·NNorthwestern University·Phase 1·NCT00424489·9 enrolled

PrEP1 trial

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Completed·MM.D. Anderson Cancer Center·N/A·NCT01490060·47 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03663933·71 enrolled

Idiopathic Inflammatory Myopathy1 trial

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Terminated·NNorthwestern University·Phase 1·NCT00278564·7 enrolled

Hematologic Cancer1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Recruiting·IIndapta Therapeutics, INC.·Phase 1/2·NCT06119685·128 enrolled

AIN1 trial

Autologous Transplant Targeted Against Crohn's

Withdrawn·NNorthwestern University·Phase 2·NCT04154735

Treatment1 trial

Cysteine-lowering Treatment With Mesna

Completed·UUniversity of Oslo·Phase 1·NCT04449536·25 enrolled

CNS Embryonal Tumor1 trial

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04530565·348 enrolled

AML1 trial

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

Recruiting·CCERo Therapeutics Holdings, Inc.·Phase 1·NCT06834282·18 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination w Sirolimus and Mycophenolate Mofetil as GVHD Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05436418·260 enrolled

Hematologic Neoplasms1 trial

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04959175·320 enrolled

Metastatic Melanoma1 trial

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05470283·21 enrolled

Central Nervous System Nongerminomatous Germ Cell Tumor1 trial

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Recruiting·CChildren's Oncology Group·Phase 2·NCT04684368·160 enrolled

Liver1 trial

A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03577431·9 enrolled

Splenomegaly1 trial

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06345495·30 enrolled

Aplastic Anemia1 trial

Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04558736·21 enrolled

Acute Lymphoblastic Leukemia (ALL)1 trial

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03849651·69 enrolled

Germ Cell Tumors1 trial

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01873326·92 enrolled

Unspecified3 trials

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00958256·22 enrolled

MESNA Injection for TMJ Internal Derangement

Completed·TTanta University·N/A·NCT05882604·60 enrolled

Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital

Unknown status·—·Phase 4·NCT03172052·100 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 30, 1988

MESNEX

NDA NDA019884

Dec 30, 1988

MESNEX

NDA NDA019884

Apr 22, 1993

MESNEX

NDA NDA019884

Nov 16, 1994

MESNEX

NDA NDA019884

Sep 25, 1995

MESNEX

NDA NDA019884

May 23, 1996

MESNEX

NDA NDA019884

Jul 26, 2000

MESNEX

NDA NDA019884

Mar 21, 2002

MESNEX

NDA NDA020855

Jan 30, 2003

MESNEX

NDA NDA019884

Jan 30, 2003

MESNEX

NDA NDA019884

Dec 28, 2012

MESNEX

NDA NDA020855

Mar 17, 2014

MESNEX

NDA NDA020855

Mar 17, 2014

MESNEX

NDA NDA019884

Feb 26, 2016

MESNEX

NDA NDA019884

Dec 17, 2018

MESNEX

NDA NDA020855

Dec 17, 2018

MESNEX

NDA NDA019884

Sources

References

[1]
ClinicalTrials.gov — 168 trial records for mesna. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Mesnex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — mesna compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for mesna. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020855). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Mesnex

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Lymphoma17 trials

Acute Lymphoblastic Leukemia14 trials

Leukemia9 trials

Neuroblastoma8 trials

Breast Cancer7 trials

Stem Cell Transplantation6 trials

Bone Marrow Transplantation5 trials

Soft Tissue Sarcoma5 trials

Systemic Sclerosis4 trials

Multiple Sclerosis3 trials

Chemotherapy3 trials

Osteosarcoma3 trials

Acute Lymphoblastic Leukaemia2 trials

Hematological Malignancies2 trials

Mantle Cell Lymphoma2 trials

Germ Cell Tumor2 trials

Medulloblastoma2 trials

Hematologic Malignancies2 trials

Hematopoietic Stem Cell Transplant2 trials

Memory2 trials

Retinoblastoma2 trials

Stem Cell Transplant2 trials

Transplantation2 trials

Ependymoma2 trials

Sickle Cell Disease2 trials

Melanoma2 trials

Acute Lymphoblastic Leukemia, in Relapse2 trials

Ewing's Sarcoma1 trial

Liver Transplant1 trial

Vasculitis1 trial

Severe Aplastic Anemia1 trial

Myeloid Malignancies1 trial

Tolerance1 trial

NMO Spectrum Disorder1 trial

Fibrosarcoma1 trial

Lymphoid Malignancies1 trial

Adenocarcinoma1 trial

Kidney Cancer1 trial

Necrosis1 trial

Radiation Therapy1 trial

Solid Tumors1 trial

Ewing sarcoma1 trial

Multiple Myeloma1 trial

APL1 trial

Small Cell Lung Cancer1 trial

Metastatic Cancer1 trial

Kidney Failure1 trial

CNS Tumors1 trial

Hematopoietic Cell Transplantation (HCT)1 trial

TED1 trial

Vomiting1 trial

Thalassemia1 trial

Autologous Stem Cell Transplantation1 trial

Patients With Solid Tumors1 trial

Graft-versus-host-disease (GVHD)1 trial

Hematopoietic Cell Transplantation1 trial

Hematologic Malignancy1 trial

Systemic Lupus Erythematosus1 trial

Randomized1 trial

Myasthenia Gravis1 trial

PrEP1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Idiopathic Inflammatory Myopathy1 trial

Hematologic Cancer1 trial

AIN1 trial

Treatment1 trial

CNS Embryonal Tumor1 trial

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial

AML1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Hematologic Neoplasms1 trial

Metastatic Melanoma1 trial

Central Nervous System Nongerminomatous Germ Cell Tumor1 trial